Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 21,893 shares, an increase of 184.6% from the April 30th total of 7,692 shares. Based on an average trading volume of 13,051 shares, the short-interest ratio is currently 1.7 days.
Relief Therapeutics Stock Up 1.3%
RLFTF stock traded up $0.01 during mid-day trading on Friday, reaching $0.48. The company’s stock had a trading volume of 2,359 shares, compared to its average volume of 3,382. Relief Therapeutics has a fifty-two week low of $0.33 and a fifty-two week high of $4.88. The company’s 50 day moving average is $0.47 and its two-hundred day moving average is $1.55.
About Relief Therapeutics
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Featured Stories
- Five stocks we like better than Relief Therapeutics
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
